Generic Name and Formulations:
Tazarotene 0.1%; crm.
Indications for AVAGE:
Adjunct to comprehensive skin care and sunlight avoidance programs in the palliation of facial fine wrinkles, facial mottled hyper- and hypopigmentation, and facial benign lentigines.
Limitations Of use:
Does not eliminate or prevent wrinkles or restore more youthful skin. Does not reverse photoaging or repair sun damaged skin; does not mitigate coarse or deep wrinkling, tactile roughness, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, or dermal elastosis. The safety and effectiveness for the prevention or treatment of actinic keratoses, skin neoplasms, or lentigo maligna have not been established.
≥17yrs: apply thin film to entire face once daily in the PM. Females of reproductive potential: begin therapy during normal menses.
<17yrs: not established.
Assess any facial pigmented lesions (eg, lentigo maligna) prior to initiation. Obtain reliable negative pregnancy test within 2 weeks prior to therapy. Females of reproductive potential should use effective contraception. Do not use on broken, eczematous, or sunburned skin. Sun sensitivity. Avoid eyes, mouth, sun, and UV light. Increased irritation in extreme weather. Discontinue or reduce dose frequency if excessive irritation occurs. Nursing mothers.
Avoid use until the effects of strong drying agents have subsided. Avoid concomitant with photosensitizers or other irritants.
Desquamation, erythema, burning, dry or irritation skin, pruritus, irritant contact dermatitis, stinging, rash, cheilitis.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes In on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma